Literature DB >> 9255237

Fosfomycin for urinary tract infections.

.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9255237

Source DB:  PubMed          Journal:  Med Lett Drugs Ther        ISSN: 0025-732X            Impact factor:   1.909


× No keyword cloud information.
  5 in total

1.  Ex Vivo Urinary Bactericidal Activity and Urinary Pharmacodynamics of Fosfomycin after Two Repeated Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Subjects.

Authors:  E Wenzler; K M Meyer; S C Bleasdale; M Sikka; R E Mendes; K L Bunnell; M Finnemeyer; S L Rosenkranz; L H Danziger; K A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

2.  The Uropathogenic Escherichia coli Subclone Sequence Type 131-H30 Is Responsible for Most Antibiotic Prescription Errors at an Urgent Care Clinic.

Authors:  Veronika Tchesnokova; Kim Riddell; Delia Scholes; James R Johnson; Evgeni V Sokurenko
Journal:  Clin Infect Dis       Date:  2019-02-15       Impact factor: 9.079

3.  Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial.

Authors:  Angela Huttner; Anna Kowalczyk; Adi Turjeman; Tanya Babich; Caroline Brossier; Noa Eliakim-Raz; Katarzyna Kosiek; Begoña Martinez de Tejada; Xavier Roux; Shachaf Shiber; Ursula Theuretzbacher; Elodie von Dach; Dafna Yahav; Leonard Leibovici; Maciek Godycki-Cwirko; Johan W Mouton; Stephan Harbarth
Journal:  JAMA       Date:  2018-05-01       Impact factor: 56.272

Review 4.  Nitrofurantoin and fosfomycin for resistant urinary tract infections: old drugs for emerging problems.

Authors:  Bradley J Gardiner; Andrew J Stewardson; Iain J Abbott; Anton Y Peleg
Journal:  Aust Prescr       Date:  2019-02-01

5.  Multiple-Dose Oral Fosfomycin for Treatment of Complicated Urinary Tract Infections in the Outpatient Setting.

Authors:  Catherine G Derington; Nancy Benavides; Thomas Delate; Douglas N Fish
Journal:  Open Forum Infect Dis       Date:  2020-01-29       Impact factor: 3.835

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.